Seven patients (25.9%) received two diagnoses, most frequently parkinsonism and dyskinesia. Keywords: clebopride; iatrogenic; dopamine blocker; tardive syndrome; dyskinesia EN clebopride iatrogenic dopamine blocker tardive syndrome dyskinesia 1562 1563 2 10/24/23 20231001 NES 231001 During the last months, we found an unusually high number of patients with movement disorders after clebopride, a dopamine antagonist with a selective affinity for dopamine D2 receptors used to treat functional gastrointestinal disorders.[1] Here, we describe five new cases (Video 1 and Table S1). Other movement disorders included dyskinesia (40.7%, mainly oromandibular), dystonia (25.9%), and akathisia, restless legs, and rabbit syndrome in one patient each. [Extracted from the article]